MicroRNA and Cancer Treatment: A Commentary

www.thecancerpress.com Corresponding Author E-Mail: Heidarzade_samane@yahoo.com 13 References 1. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993 Dec;75(5):843–54. 2. Aherne ST, O’Neill F, Madden SF, Clynes M, Lynch CC. Abstract 1091: miR-125 family of miRNAs mediates prostate cancer cell proliferation and migration. Cancer Res. 2016;76(14 Supplement). 3. Al-Ali BM, Ress AL, Gerger A, Pichler M. MicroRNAs in renal cell carcinoma: implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer Res. 2012 Sep;32(9):3727–32. 4. Acunzo M, Romano G, Wernicke D, Croce CM. MicroRNA and cancer – A brief overview. Adv Biol Regul. 2015;57:1–9. 5. Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015 May;15(6):321–33. 6. Coley HM, Stebbing J, Glassman R, Nabholtz JM, Reese DM, Lindsay MA, et al. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev. 2008 Jun;34(4):378–90. 7. Oak PS, Kopp F, Thakur C, Ellwart JW, Rapp UR, Ullrich A, et al. Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positive cancer cells and cancer stem cells. Int J Cancer. 2012 Dec;131(12):2808–19. Vol. 3, No.1, March, 2017 Vol 3, No 1, March, 2017, P 13-15 DOI, 10.15562/tcp.38